血清糖化血红蛋白和IL-6对非酒精性脂肪性肝病发病风险的预测价值探讨*

doi:10.3969/j.issn.1672-5069.2020.02.013

摘要/Abstract

摘要： 目的探讨血清糖化血红蛋白(HbA1c)和白细胞介素-6(IL-6)预测非酒精性脂肪性肝病(NAFLD)发病风险的价值。方法 2014年3月～2015年9月在我院行体检的健康人群658名,进行为期3年的随访。采用酶联免疫吸附法测定血清IL-6水平,应用Logistic回归分析NAFLD发生的独立危险因素。结果在658名体检人群中,随访发现86例(13.1%)发生NAFLD;NAFLD患者BMI为(26.4±2.5)kg/m²,显著大于572例健康人[(21.3±2.6) kg/m²,P＜0.05];NAFLD患者血清ALT、AST和GGT水平分别为(55.1±7.2)U/L、(63.1±9.3)U/L和(73.6±6.2)U/L,显著高于健康人[分别为(23.5±6.3)U/L、(21.7±4.4)U/L和(25.1±6.4)U/L,P＜0.05];NAFLD患者血TG、LDL-C、FPG和2hPG分别为(2.5±1.1)mmol/L、(1.1±0.2)mmol/L、(5.8±1.0)mmol/L 和(7.6±2.3)mmol/L,与健康人[分别为(1.2±0.3)mmol/L、(1.4±0.3)mmol/L、(5.0±0.8)mmol/L 和(6.6±2.1)mmol/L,P＜0.05]比,差异显著;NAFLD患者血清HbA1c为(6.0±0.9)%,显著高于健康人[(5.0±0.6)%,P＜0.05],NAFLD患者血清IL-6水平为(13.3±4.2)ng/L,显著高于健康人[(3.1±0.8)ng/L,P＜0.05];多元Logistic回归分析结果显示HbA1c(OR=1.355,95%CI:1.121～2.315)和IL-6(OR=1.368,95%CI:1.056～2.685)是NAFLD发生的独立危险因素。结论血清HbA1c和IL-6异常升高对NAFLD的诊断具有一定的预测价值,值得进一步研究。

关键词: 非酒精性脂肪性肝病, 糖化血红蛋白, 白细胞介素-6, 预测

Abstract: Objective The aim of this study was to explore the predictive value of serum glycosylated hemoglobin (HbA1c) and interleukin-6 (IL-6) levels on the risk of nonalcoholic fatty liver disease (NAFLD). Methods A total of 658 individuals were recruited in this study, and all of them underwent a comprehensive physical examination in our hospital between March 2014 and September 2015. Blood HbA1c and serum IL-6 levels were assayed, and Logistic analysis was applied to show the independent risk factors for NAFLD. Results Out the 658 individuals for physical check-up, 86 cases(13.1%) were found having NAFLD during the three-year follow-up by sonography; the BMI in patients with NAFLD was (26.4±2.5)kg/m², significantly higher than [(21.3±2.6) kg/m², P＜0.05] in 572 healthy persons; serum ALT, AST and GGT levels in patients with NAFLD were (55.1±7.2)U/L, (63.1±9.3)U/L and (73.6±6.2)U/L, significantly higher than [(23.5±6.3)U/L, (21.7±4.4)U/L and(25.1±6.4)U/L, respectively, P＜0.05] in the healthy persons; blood TG, LDL-C,FPG and2hPG levels in patients with NAFLD were (2.5±1.1)mmol/L,(1.1±0.2)mmol/L,(5.8±1.0)mmol/L and (7.6±2.3)mmol/L, significantly different as compared to [(1.2±0.3)mmol/L, (1.4±0.3)mmol/L,(5.0±0.8)mmol/L and (6.6±2.1)mmol/L, respectively, P＜0.05] in healthy persons; blood HbA1c in patients with NAFLD was (6.0±0.9)%, significantly higher than [(5.0±0.6)%, P＜0.05] and serum IL-6 level was (13.3±4.2)ng/L, significantly higher than [(3.1±0.8)ng/L, P＜0.05] in the healthy persons; Logistic analysis showed than elevated blood HbA1c(OR=1.355, 95%CI:1.121-2.315) and serum IL-6 levels(OR=1.368, 95%CI:1.056-2.685) were the risk factors for the occurrence of NAFLD. Conclusion Abnormal elevation of serum glycosylated hemoglobin and IL-6 levels might hint to a certain degree the happening of nonalcoholic fatty liver disease in the future, which must be concerned in clinical practice.

Key words: Nonalcoholic fatty liver disease, Glycated hemoglobin, Interleukin-6, Prediction

叶晓贤, 杨丽, 雷丽. 血清糖化血红蛋白和IL-6对非酒精性脂肪性肝病发病风险的预测价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 199-202.

Ye Xiaoxian, Yang Li, Lei Li. Predictive value of serum glycosylated hemoglobin and IL-6levels on the risk of nonalcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2020, 23(2): 199-202.

参考文献

[1] 严霜霜,尹立雪.NAFLD心血管并发症超声心动图研究进展.中华超声影像学杂志,2018,27(6): 545-548.
[2] Issa D, Albeldawi M, Lopez R, et al. Hematocrit levels and red blood cell indices in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 2014, 26(3): 363-364.
[3] Katoh S, Peltonen M, Wada T, et al. Fatty liver and serum cholinesterase are independently correlated with HbA1c levels: cross-sectional analysis of 5384 people .J Int Med Res, 2014, 42(2): 542-553.
[4] Sherwani SI, Khan HA, Ekhzaimy A, et al. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insig, 2016, 11(10): 95-104.
[5] Prystupa A, Kiciński P, Sak J, et al. Proinflammatory cytokines (IL-1α, IL-6) and hepatocyte growth factor in patients with alcoholic liver cirrhosis. Gastroenterol Res Pract, 2015, 12(6): 1-7.
[6] Hossain IA, Rahman Shah MM, Rahman MK, et al. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD. Diabetes Metab Syndr, 2016, 10(1): 25-29.
[7] Kawanaka M, Nishino K, Oka T, et al. Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease.Hepat Med, 2015, 7(1): 29-35.
[8] 邵庆华, 郑盛, 杨涓, 等. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平变化研究. 实用肝脏病杂志, 2016, 19(2): 175-179.
[9] Mohan A, Reddy SA, Sachan A, et al. Derivation and validation of glycosylated haemoglobin(HbA1c)cut-off value as a diagnostic test for type 2 diabetes in south Indian population. Ind J Med Res, 2016, 144(2): 220-228.
[10] 杨毅, 韩晨阳, 官俏兵, 等. 白细胞介素17通过促进巨噬细胞M1型极化调控小鼠非酒精性脂肪性肝病组织炎症反应的机制. 中华肝脏病杂志, 2018, 26(12): 916-921.
[11] Bhala N, George J. The burden of non-alcoholic fatty liver disease (NAFLD) in the Asia pacific region. Curr Hepatol Rep, 2015, 14(2): 77-86.
[12] Mahale AR, Prabhu SD, Nachiappan M, et al. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups.J Int Med Res, 2018, 46(11): 4447-4454.
[13] 陈长喜, 杜娟, 徐益敏, 等. 血清糖化血红蛋白对非酒精性脂肪性肝病发病风险的预测价值. 中华肝脏病杂志, 2018, 26(10): 765-770.
[14] 陈长喜, 杜娟, 徐益敏, 等. 中老年人NAFLD与糖化血红蛋白关系的流行病学研究. 中华内科杂志, 2015, 54(6): 517-520.
[15] Shi DM, Dong FY, Zhang F, et al. IL-6 trans-signaling in an L-02 fatty liver cell model induced with sodium oleate and sodium palmitate. World Chin J Digestol, 2014, 22(34): 5235-5241.
[16] Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol, 2016, 64(6): 1403-1415.
[17] Zaki ME, Nazif HK, Kandeel W, et al. IL-6 174G/C polymorphism in obese adolescents with nonalcoholic fatty liver disease and its relation to metabolic and biochemical markers. Middle East J Med Genet, 2016, 5(1): 20-25.
[18] Zhang F, Jiang W, Li X, et al. The role of intrahepatic B cells in non-alcoholic fatty liver disease through secretion of pro-inflammatory cytokines and regulation of intrahepatic T cells. J Dig Dis, 2016, 17(7): 464-474.
[19] Olteanu S, Kandel-Kfir M, Shaish A, et al. Lack of interleukin-1α in Kupffer cells attenuates liver inflammation and expression of inflammatory cytokines in hypercholesterolaemic mice. Dig Liver Dis, 2014, 46(5): 433-439.
[20] Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials, 2014, 9(3): 134-140.

血清糖化血红蛋白和IL-6对非酒精性脂肪性肝病发病风险的预测价值探讨^*

Predictive value of serum glycosylated hemoglobin and IL-6levels on the risk of nonalcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张猛, 陈晹, 刘娇, 李叶晟, 黄杨卿. 非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因FAS、ACC和SREBP-1水平分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 163-166.
[2]	姜佳丽, 李莉, 赵菲, 钟乐萍, 郭子皓, 张川, 展玉涛. 非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 167-170.
[3]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[4]	刘继国, 窦翠云, 程广玲. NAFLD合并T2DM患者糖化血红蛋白和甲状腺激素水平的变化及其临床意义^*[J]. 实用肝脏病杂志, 2020, 23(2): 207-210.
[5]	曾震军, 李墨航. 血清学指标和脂肪肝指数诊断非酒精性脂肪性肝病价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 211-214.
[6]	王丽娟, 朱兵兵, 胡敏华, 杨丽, 石莉红, 胡健薇. 匹伐他汀与阿托伐他汀治疗非酒精性脂肪性肝病患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(2): 215-218.
[7]	任国亮, 李连生, 刘刚, 丰帆, 刘婧. 热量限制饮食对非酒精性脂肪性肝病患者胰岛素抵抗、血脂和氧化应激指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 219-222.
[8]	陈丽丽, 符茂雄, 蒙绪标, 方其超. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 38-41.
[9]	柳健, 朱峰发, 唐娟. 非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*[J]. 实用肝脏病杂志, 2020, 23(1): 42-45.
[10]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[11]	毛重山, 殷辉, 肖二辉, 张英英. 非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 50-53.
[12]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.
[13]	郭化磊, 卜理琳, 裴颖, 殷宏振, 黄峰. 化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化^*[J]. 实用肝脏病杂志, 2020, 23(1): 138-141.
[14]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[15]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.